UNIVERSITY OF BIRMINGHAM

University of Birmingham Research at Birmingham

Distribution of plasma oxidised phosphatidylcholines in chronic kidney disease and periodontitis as a co-morbidity

Ademowo, Opeyemi Stella; Sharma, Praveen; Cockwell, Paul; Reis, Ana; Chapple, Iain; Griffiths, Helen R.; Dias, Irundika H. K.

DOI:
10.1016/j.freeradbiomed.2019.10.012

License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version
Peer reviewed version

Citation for published version (Harvard):
Ademowo, OS, Sharma, P, Cockwell, P, Reis, A, Chapple, I, Griffiths, HR & Dias, IHK 2020, 'Distribution of plasma oxidised phosphatidylcholines in chronic kidney disease and periodontitis as a co-morbidity', *Free Radical Biology and Medicine*, vol. 146, pp. 130-138. https://doi.org/10.1016/j.freeradbiomed.2019.10.012

Link to publication on Research at Birmingham portal

Publisher Rights Statement:
Ademowo, OS, Sharma, P, Cockwell, P, Reis, A, Chapple, I, Griffiths, HR & Dias, IHK (2019), 'Distribution of plasma oxidised phosphocholines in chronic kidney disease and periodontitis as a co-morbidity', Free Radical Biology and Medicine, pp. 1-26. https://doi.org/10.1016/j.freeradbiomed.2019.10.012

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.
•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
•User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
•Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 01. Jun. 2024

1 **Distribution of plasma oxidised phosphocholines in chronic kidney disease and**
2 **periodontitis as a co-morbidity**

3 Opeyemi Stella Ademowo[1], Praveen Sharma[2], Paul Cockwell[3], Ana Reis[4], Iain L Chapple[2], Helen
4 R Griffiths[5, 6], Irundika HK Dias[6*]

5 1. Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0AH, UK

6 2. Periodontal Research Group, University of Birmingham, and Birmingham Community
7 Healthcare Trust, Birmingham, England

8 3. Renal Medicine, University Hospital Birmingham Foundation Trust, Birmingham, England

9 4. LAQV/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences,
10 University of Porto, 4169-007 Porto, Portugal

11 5. Faculty of Health and Medical Sciences, University of Surrey, Stag Hill, Guildford, GU2 7XH,
12 UK

13 6. Aston Medical Research Institute, Aston Medical School, Aston University, Birmingham, B4
14 7ET, UK

15 *Corresponding author

16 Email: h.k.i.dias1@aston.ac.uk

17

18

19

20

21

22

23

24

25

26

27

28

Abstract

Individuals with chronic kidney disease (CKD) and periodontitis as a co-morbidity have a higher mortality rate than individuals with CKD and no periodontitis. The inflammatory burden associated with both diseases contributes to an increased risk of cardiovascular and all-cause mortality. We previously demonstrated that periodontitis is associated with increasing circulating markers of inflammation and oxidative stress. We propose that inflammatory oxidised phosphocholines may contribute to the increased risk of cardiovascular disease in patients with CKD. However, the analysis of oxidised phospholipids has been limited by a lack of authentic standards for absolute quantification. Here, we have developed a comprehensive quantification liquid chromatography-mass spectrometry-based multiple reaction monitoring method for oxidised phospholipids (including some without available authentic species) that enables us to simultaneously measure twelve oxidised phosphocholine species with high levels of sensitivity and specificity. The standard curves for commercial standards 1-palmitoyl-2-glutaryl-*sn*-glycero-3-phosphocholine (PGPC); 1-palmitoyl-2-(9'-oxo-nonanoyl)-*sn*-glycero-3-phosphocholine (PONPC), 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PAzPC) and 1-palmitoyl-2-(5'-oxo-valeroyl)-*sn*-glycero-3-phosphocholine (POVPC), were linear with a correlation coefficient greater than 0.99 for all analytes. The method is reproducible, with intra- and inter-day precision <15%, and accuracy within ±5% of nominal values for all analytes. This method has been successfully applied to investigate oxidised phosphocholine in plasma from CKD patients with and without chronic periodontitis and the data that was obtained has been compared to plasma from healthy controls. Comparative analysis demonstrates altered chain fragmented phosphocholine profiles in the plasma samples of patients with CKD and periodontitis as a co-morbidity compared to healthy controls.

Key words: CKD, periodontitis, oxidised phospholipids, MRM-LC/MS, oxidative stress

Abbreviations

CV	Coefficient of variation
CKD	Chronic kidney disease
dDMPC	1, 2-dimyristoyl-*sn*-glycerol-3-phosphocholine-1,1,2,2-d4-N,N,N-trimethyl-d9
MRM	Multiple reaction monitoring
OxPC	Oxidized phosphocholine
PAPC	1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine
PAzPC	1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine
PGPC	1-palmitoyl-2-glutaryl-*sn*-glycero-3-phosphocholine
PL	Phospholipid
PLPC	1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine
PONPC	1-palmitoyl-2-(9'-oxo-nonanoyl)-*sn*-glycero-3-phosphocholine
POVPC	1-palmitoyl-2-(5'-oxo-valeroyl)-*sn*-glycero-3-phosphocholine
PPD	Probing pocket depth
QC	Quality control
ROS	Reactive oxygen species
SAPC	1-stearoyl-2-arachidonoyl-*sn*-glycero-3-phosphocholine
SAzPC	1-stearoyl-2-azelaoyl-sn-glycero-3-phosphocholine
SD	Standard deviation
SE	Standard error
SGPC	1-stearoyl-2-glutaryl-*sn*-glycero-3-phosphocholine
SLPC	1-stearoyl-2-linoleoyl-*sn*-glycero-3-phosphocholine
SONPC	1-stearoyl -2-(9'-oxo-nonanoyl)-*sn*-glycero-3-phosphocholine
SOVPC	1-stearoyl-2-(5'-oxo-valeroyl)-*sn*-glycero-3-phosphocholine
TLR	Toll like receptors

105 **1. Introduction**

106 Chronic kidney disease (CKD) affects up to 16% of the population worldwide, increases in
107 prevalence with age and is associated with high morbidity and mortality compared to
108 individuals without CKD [1, 2]. Traditional risk factors for CKD such as age, gender, ethnicity,
109 family history, smoking habits, and socioeconomic status are also associated with diabetes,
110 hypertension, and lipid disorder comorbidities; individually and collectively these contribute
111 to a higher cardiovascular disease morbidity and mortality [3]. Non-traditional risk factors are
112 also associated with poorer CKD outcomes, including inflammation, which is strongly
113 associated with an increased risk of progression to end-stage renal failure and mortality [1].
114 Identifying and targeting novel, modifiable risk factors that contribute to systemic
115 inflammation in CKD and are causal for poorer clinical outcomes represents an effective
116 strategy for reducing morbidity and mortality in those affected [4].

117 Periodontitis is the most common chronic inflammatory disease of humans, affecting about
118 40-50% of the global population and in its most severe form is the sixth most common human
119 disease (11.2%)[5]. The global burden of periodontitis increased from 1990 to 2010 by 57.3%
120 [6]. Indeed, oral diseases, including periodontitis were the leading causes of non-fatal health
121 loss in males and females, determined by years lived with disability, in The Global Burden of
122 Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017). Periodontitis leads to significant
123 elevations in both acute-phase reactants (CRP, IL-6) [5, 7] and oxidative stress biomarkers in
124 plasma [8]. Our previous work demonstrated that CKD patients who are at high risk of
125 progression to end-stage renal disease [9], had a significantly greater prevalence (88%) and
126 severity of periodontitis compared to a local, community dwelling control population (55%)
127 [10]. Using survival analysis carried out in the Third National Health and Nutrition Examination
128 Survey (NHANES III) of the USA and linked mortality data, we demonstrated a strong
129 association between periodontitis and increased mortality in individuals with CKD [10, 11].
130 Given the existing oxidative stress burden in periodontitis [8], others have analysed the
131 plasma oxidation status of patients with CKD and found that the lipid peroxidation product
132 F2-isoprostane was elevated [12].

133 The unsaturated fatty acid chains present in sn-1 or sn-2 position of phospholipids (PLs) can
134 undergo either enzymatic (e.g. by lipoxygenases) or non-enzymatic oxidation (by reactive
135 oxygen species; ROS such as the hydroxyl radical, superoxide anion, peroxynitrite,
136 hypochlorite anion and peroxide) to yield oxidised phospholipids (oxPLs) and after release by
137 phospholipases, to form isoprostane species. Oxidative modifications include oxidation of the
138 unsaturated fatty acid chains, intra- and intermolecular arrangements, cyclisation and
139 fragmentation [13].These full-chain oxidised PLs along with chain fragmented PLs may initiate
140 and modulate inflammatory reactions and have been implicated in the pathogenesis of age-
141 related diseases [14, 15]. OxPLs act as lipid mediators of cellular and immune signaling via Toll
142 like receptors (TLR) and are potential biomarkers of disease pathogenesis [14, 16].
143 Phosphocholine (PC) species with sn-2 palmitoyl or stearoyl moieties comprising; 1-palmitoyl-

144 2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC), 1-palmitoyl-2-linoleoyl-sn-glycero-3-
145 phosphocholine (PLPC) 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (SAPC) and 1-
146 stearoyl-2-linoleoylphosphatidylcholine (SLPC) were shown to generate several discrete
147 oxidised phospholipids under different conditions [14, 17]. The oxidised phosphocholines
148 (oxPCs) generated have immunogenic activity and act as ligands for scavenger receptors [17].
149 Oxidised metabolites are rapidly removed in plasma by cellular uptake and detoxified through
150 catabolic activity in the liver [13].

151 Our understanding of oxPCs, including their concentration in biological fluids, cells and
152 tissues, is emerging with the aid of quantitative lipidomics. It is important to establish reliable
153 and simplified mass spectrometry methods to analyse oxPCs [18]. However, the major
154 challenge in quantitative oxidative lipidomics is the availability of authentic and deuterated
155 standards for the lipids of interest [13, 19]. To mitigate this limitation, we have prepared
156 additional oxidised products of PAPC, PLPC, SAPC and SLPC using Fenton reaction chemistry
157 to expand the panel of oxPCs.

158 In this paper we describe a mass spectrometry based multiple reaction monitoring (MRM)
159 method that enables measurement of an extensive panel of oxPCs to investigate the plasma
160 oxPC profiles of patients with CKD and CKD with co-morbid periodontitis compared to healthy
161 controls. Using this method, we investigated the hypothesis that CKD and CKD co-morbid with
162 periodontitis have altered oxPC profiles in plasma compared to healthy controls.

163 2. Materials and methods

164 2.1 Chemicals

165 Authentic lipid standards comprising: 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-
166 phosphocholine (POVPC); 1-palmitoyl-2-(9'-oxo-nonanoyl)-*sn*-glycero-3-phosphocholine
167 (PONPC); - 1-palmitoyl-2-glutaryl-*sn*-glycero-3-phosphocholine (PGPC); 1-palmitoyl-2-
168 azelaoyl-sn-glycero-3-phosphocholine (PAzPC), 1-stearoyl-2-arachidonoyl-sn-glycero-3-
169 phosphocholine (SAPC) and 1-stearoyl-2-linoleoylphosphatidylcholine (SLPC) and one
170 deuterated standard; 1, 2-dimyristoyl-*sn*-glycero-3-phosphocholine 1, 1, 2, 2-d_4-N, N, N-
171 trimethyl-d_9 (dDMPC), were purchased from Avanti Polar Lipids (Alabaster, USA). Solvents for
172 lipid extraction and LC-MS of HPLC grade were purchased from Fisher Scientific,
173 Loughborough, UK. All other chemicals were purchased form Sigma Aldrich (Dorset, UK),
174 unless otherwise stated.

175 2.2 *In vitro* oxidation of SAPC and SLPC and extraction of oxidised lipids

176 SAPC and SLPC were oxidised with $FeCl_2$ and H_2O_2 (Fenton reaction) according to the method
177 described by Reis *et al*. [20]. Briefly, 100µg of phospholipids were oxidised with 50mM H_2O_2 /
178 5mM $FeCl_2$ in 1ml solution. The mixture was allowed to react at 37°C in the dark with
179 sonication and occasional vortexing. Oxidation was monitored by electrospray ionisation
180 mass spectrometry at 24hrs and 48hrs. Products of lipid peroxidation resulted from cleavage

181 of oxygen radicals producing short chain aldehydes, hydroxyaldehydes and dicarboxylic acids.
182 Phospholipid oxidation products were extracted using the modified methyl tert butyl ether
183 (MTBE) method with MTBE/methanol/water (10:3:2.5, v/v/v) containing 50µg/ml of BHT as
184 we previously described [21].

185 **2.3 Plasma samples**

186 Plasma samples were from a randomly selected group of patients with CKD, and who were
187 periodontally healthy (n=13) recruited to the Renal Impairment in Secondary Care (RIISC)
188 study (Ethical approval for this cohort was covered by West Midlands South Birmingham NRES
189 10/H1207/6) [10]. The RIISC study is an ongoing, prospective cohort study investigating novel
190 risk factors in the progression of CKD. Further plasma samples were collected from patients
191 with CKD and with periodontitis as a comorbidity (n=20), patients with periodontitis without
192 any self-reported illness (n=17), and without periodontitis or CKD (n=20) in the "INSPIRED
193 TRIAL" (Influence of Successful Periodontal Intervention on Renal and Vascular Systems in
194 patients with Chronic Kidney Disease-A Pilot Interventional Randomised Controlled Trial
195 (INSPIRED). Ethical approval was by the National Research Ethics Service, West Midlands -
196 The Black Country, ref 15/WM/0006) [22]. The INSPIRED trial is an ongoing pilot randomised
197 control trial investigating the effect of periodontal treatment on the cardio-renal health of
198 patients with CKD. The patient demographics are shown in **table 1**. Blood samples were
199 collected in the EDTA tubes and plasma was separated by centrifugation for 10 min at 3000×g
200 at 4 °C within 2 hours of withdrawal and frozen at -80°C until further analysis.

201 Inclusion criteria for all participants were: patients aged ≥18 years; able to provide consent to
202 participate in the trial. Additional inclusion criteria for patients with CKD, for patients with
203 CKD and periodontitis, and for systemically healthy patients with periodontitis are detailed as
204 supplementary material.

205 Exclusion criteria for all participants were: patients not meeting the inclusion criteria; or
206 unable to provide informed consent. Additional exclusion criteria for patients with CKD, for
207 systemically healthy patients with periodontitis, and for systemically healthy patients without
208 periodontitis are detailed as supplementary material.

209 For the purposes of this study, periodontitis is defined as those with a cumulative probing
210 depth ≥30 mm. This is the sum of the deepest probing pocket per tooth, excluding probing
211 depths <5 mm. This represents generalised moderate-severe periodontitis (periodontal
212 health=1).

213 **2.4 MTBE lipid extraction**

214

215 Lipids were extracted from 10µl of individual plasma samples spiked with 200ng of dDMPC
216 internal standard by MTBE method as previously reported [21]. The dried lipid extracts were

reconstituted in 200µl methanol immediately prior to injection. Lipid extracts (10µl in 100% methanol) were injected for separation and analysis by LC-MS/MS.

2.5 Phospholipid quantification

For the purpose of phospholipid assay, lipids were extracted from 10 µl of plasma by the Folch protocol [23]. Phospholipid content of lipid extracts was quantified by spectrophotometry measurement of inorganic phosphorous (λ=797 nm) using a micromethod adapted from Rouser et al. [24], as described before [25].

2.6 Liquid chromatography-mass spectrometry (LC-MS/MS) analysis of lipids

Our previously described MRM-MS method [21] was adapted using the triple quadrupole mass spectrometer (QTRAP 5500, AB Sciex UK Ltd. Warrington) equipped with a standard-ESI source, operated in a positive ion mode with an ionisation voltage of 5kV, entrance potential of 10 V, and ion source temperature of 400 °C, collision gas nitrogen 20V and ion source gas 25V. For optimisation of ESI and MS parameters, standard mixtures containing 1ng/µl of each oxPC species was infused directly to the ESI source through an integrated syringe pump (Harvard apparatus) with a flow rate of 20µl/min. Lipid extracts were separated on a Luna Omega C18 column (internal diameter 2.1mm, column length 50mm, particle size 3µm, Phenomenex, Macclesfield, Cheshire, UK) with column guard installed. Mobile phases consisted of (A) 10 mM ammonium formate in methanol: water: formic acid (20:80:0.1, v/v/v) and (B) 2 mM ammonium formate in 2-propanol: methanol: formic acid (90:10:0.1, v/v/v) at 60 °C. Flow rate was maintained at 200 µl/min with the gradient as follows: 30% B from 0 to 1 min, 30–100% B from 1 to 6 min, 100% B 6–13min, 100–30% B from 13 to 14 min, 30% B 14–24 min. Analytical samples (10µl) were injected by the autosampler at 10°C with a constant flow of 200µl/min. Measurement and data analyses were performed in triplicate using Analyst software (version 1.6.2). Peak area of the PC-specific fragment ion (*m/z* 184) which corresponds to the cleaved phosphocholine polar head was used for the quantification of oxPCs. The peak areas was normalised to the deuterated internal standard, dDMPC for each sample. Analyte concentrations in each sample was calculated using standard curves against PGPC (10-2000pg/µL), PONPC (10-1000pg/µL), PAzPC (10-1000pg/µL) and POVPC (10-500pg/µL).

2.7 Determination of linear dynamic range, limit of detection/quantification of OxPCs

The method developed was for relative quantification, however, we prepared an external calibration using authentic standards (POVPC, PGPC, PONPC and PAzPC) to determine their linear range, lower limit of detection (LOD) and lower limit of quantification (LOQ). Calibration curves were produced by injecting 6 authentic solutions between 10-2000pg/µl (10, 50, 100, 500, 1000, 2000pg/µl). The concentration ranges selected for the calibration curves were based on preliminary data on the dynamic ranges. LOD and LOQ were calculated using the blank determination method (n=20) from the International Conference on Harmonisation

(ICH) guidelines as described previously [26]. LOD and LOQ are expressed as the analyte concentration corresponding to the sample blank value plus three and ten standard deviations, respectively.

2.8 Evaluation of method reproducibility with intra-day and inter-day assays

Quality control (QC) plasma samples (n=3) were analysed to evaluate the performance of the MS response over time, namely sensitivity of the method and reproducibility. Intra-day reproducibility was obtained from six analyses run consecutively while inter-day reproducibility was obtained from ten analyses run on different days over 1 month.

2.9 Estimation of precision, accuracy, recovery and matrix effect for MRM method

The method recommended by Matuszewski *et al*. [27] was adapted for recovery and matrix effect analysis. The recovery percentages were estimated by comparing the peak areas of four concentrations (100-1000pg/ml) of POVPC, PONPC, PGPC and PAzPC standards injected in methanol to the same phosphocholine standards spiked and extracted from plasma. The accuracy of the assay was determined by six replicates of QC samples at four concentrations during a single analytical run as described by Partani et al.,[28].

2.10 Statistical analysis

Multivariable regression models were constructed with measures of oxidative stress as dependent variables and clinical health parameters (healthy/ periodontitis only/ CKD only/ CKD and periodontitis), age and gender as independent variables. All analyses were carried out using Stata/IC version 15.1 (StataCorp LLC). Significance was accepted as $p<0.05$.

285 **3. Results**

286 **3.1 Optimisation of LC-MS/MS identification of OxPC panel**

287 Four commercially available oxidised phospholipid standards, two native lipid standards
288 oxidised through Fenton chemistry and one deuterated standard were employed to develop
289 this targeted LC-MS/MS method. First, each commercially available standard was individually
290 injected to identify optimal fragments based on their abundance for MRM analysis. The
291 precursor ion scans were performed between 100 *m/z* to 1000 *m/z* mass range with ESI-MS
292 in a positive ion mode. At least three diagnostic product ions were selected for each analyte,
293 and collision energy, depolarisation potential and exit potential was optimised for each
294 transition pair (**Table 2**). The product ion spectra of $[MH]^+$ ions for POVPC, PGPC, PONPC and
295 PAzPC standards showed an abundant product ion at *m/z* 184, which corresponds to the polar
296 head group of phosphocholines ($[H_2PO_4(CH_2)_2N(CH_3)_3]^+$).

297 Next, MRM parameters were optimised to detect commercially available non-oxidised lipids;
298 PAPC, PLPC, SAPC and SLPC (**Figure 1**). To overcome the lack of standards for the
299 identification of oxidised phospholipids, we generated a panel of oxidation products using
300 PAPC, PLPC, SAPC and SLPC through the Fenton reaction between H_2O_2 and $FeCl_2$ as previously
301 described [20]. A range of oxidised phosphocholine species originating from PAPC (*m/z*
302 782.7), PLPC (*m/z* 758.7), SAPC (*m/z* 810.6) and SLPC (*m/z* 786.6) was monitored in a
303 precursor ion scan for the phospholipid head group, *m/z* 184. Aligning with previous studies
304 [14], chain-shortened, oxidised forms of SAPC were identified as 1-steroyl-2-(5'-oxo-valeroyl)-
305 sn-glycero-3-phosphocholine; SOVPC (*m/z* 622), 1-steroyl-2-glutaryl-sn-glycero-3-
306 phosphocholine; SGPC (*m/z* 638). Chain-fragmented oxidised SLPC ions were identified as 1-
307 steroyl-2-(9'-oxo-nonanoyl)-sn-glycero-3-phosphocholine; SONPC (*m/z* 678), 1-steroyl-2-
308 azelaoyl-sn-glycero-3-phosphocholine; SAzPC (*m/z* 694). Oxidised ions of PAPC were
309 identified as 1-palmitoyl-2-(5-hydroxy-8-oxo-6-octenoyl)-sn-glycero-3-phosphocholine);
310 HOOA-PC (*m/z* 648) and 1-palmitoyl-2-(5-hydroxy-8-oxo-6-octenoic acid)-sn-glycero-3-
311 phosphocholine; KOOA-PC (*m/z* 648). Chain-fragmented oxidised PLPC ions were identified
312 as 1-palmitoyl-2-(4-keto-dodec-3-enadioyl)-sn-glycero-3-phosphocholine; KDdiA-PPC (*m/z*
313 720), and 1-palmitoyl-2-(9-hydroxy-11-carboxy-undec-6-enoyl)-sn-glycero-3-
314 phosphocholine; HDdiA-PC (*m/z* 722) (**Supplementary Figure 1 and Supplementary table 1**).
315 All oxidized lipids were separated from non-oxidized lipids by reverse-phase column
316 chromatography (**Figure 2**).

317

318 **3.2 Linear dynamic range, Intra-day and inter-day analyses of MRM-MS method for OxPCs**

319 To estimate the sensitivity of the method, we estimated the linearity, LOD and LOQ of the
320 four commercially available OxPCs. The LOD and LOQ of the standard solutions were in the
321 range 0.25 - 16pg and 0.5 – 37pg respectively with all correlation coefficients greater than

322 0.99 **(Supplementary table 2).** Intra-day analyses were six consecutive analyses on the same
323 day of QC plasma sample while the inter-day analyses were ten non-consecutive analyses
324 over one month of the QC sample. The QC results show that the LC method is precise and
325 reproducible with an intra-day assay %CV of 4-8 and the inter-day %CV of 6-14.
326 (**Supplementary table 3**)

327

328

329 **3.3 Percentage recovery, matrix effect and accuracy of oxPCs standards**

330 Supplementary table 4 shows the average and the CV of oxPC recovery with and without
331 matrix; percentages are in the range 73-91% and 90-99% respectively with CVs <15%. The
332 accuracy was also 97-102%. The precision and accuracy values were satisfactory. Precision is
333 required to be within ±15% and accuracy between 85- 115% [24].

334

335 **3.4 Analysis of plasma phospholipids and oxidised phosphocholines in CKD patients with or**
336 **without periodontitis.**

337 Plasma phospholipids were analysed for phospholipid as described. Total phospholipid
338 concentration in plasma was not different between heathy and disease groups (**Figure 3**). The
339 patient demographics are described in Table 1. The distribution of patients and healthy
340 controls were not different for weight and body mass index (BMI), but significant changes
341 were observed for age and sex distribution between groups. To account for these differences,
342 multivariable regression models were constructed with measures of oxidative stress as
343 dependent variables and clinical health parameters (healthy/ periodontitis only/ CKD only/
344 CKD and periodontitis), age and sex as independent variables. Significance was accepted as
345 $p<0.05$.

346 Individual estimates of specific OxPC showed significant differences (**Figure 4 and Table 3**)
347 between healthy and disease groups. Compared to heathy subjects, patients with
348 periodontitis, CKD and with both diseases had significantly higher levels of HDdiA-PC ($P<0.05$;
349 Figure 4L). SAzPC levels were significantly higher only in CKD group compared to heathy
350 subjects ($P=0.004$; Figure 4H). KOOA-PC was significantly higher in patients with both diseases
351 than in healthy controls ($P<0.001$; Figure 4J).

352 Conversely, some oxPCs were found be significantly lower in CKD plasmas; SGPC ($P=0.009$;
353 Figure 4F), in periodontitis; POVPC ($P=0.023$; Figure 4A) and in the presence of both diseases;
354 SONPC ($P=0.033$; Figure 4G) and PAzPC ($P=0.028$; Figure 4D).

355

356

357 **4. Discussion**

358 This study has focused on developing a method to simultaneously quantify, with high
359 sensitivity, a panel of 12 oxPCs in biological fluids and applying the method to plasma samples
360 from patients with CKD and chronic periodontitis as a comorbidity for the first time. We
361 optimised chromatography conditions and included in-house oxidised lipid standards to cover
362 a panel of oxPCs. With the use of the Lunar Omega polar C18 column (Phenomenex, UK), this
363 method achieved high selectivity for polar oxidised phosphocholine lipids without diminishing
364 important non-polar interactions. By combining column characteristics with the solvent
365 system, the current method decreased the retention time of the analytes from 44 minutes to
366 24 minutes compared to our previously published method [21].

367 We and others have shown the presence of systemic inflammatory burden in periodontitis,
368 induced by periodontal bacteraemia activating peripheral blood neutrophils to release ROS
369 (6). Thus, a measure of periodontitis that captures this infectious-inflammatory exposure is
370 required. The measure used, cumulative probing depth, can be readily calculated from
371 routinely collected periodontal measurements and approximates the extent of the
372 periodontal wound. It can be used to differentiate measures of previous disease experience,
373 such as recession and clinical attachment loss, which may not influence the patient's current
374 systemic health. The current, commonly used case definitions of periodontitis may not be
375 able to achieve this, as has been reported by other researchers [29, 30]. Cumulative probing
376 depth also accounts for tooth loss in a way that other measures, such as mean probing pocket
377 depth (PPD), do not.

378 Dyslipidaemia and disturbances in lipid metabolism are reported previously in patients with
379 CKD who are pre-dialysis and who are receiving long-term renal replacement therapy with
380 haemodialysis [31, 32]. Many other studies have investigated the lipid parameters including
381 total cholesterol, high density lipoprotein cholesterol (HDL-C), Low density cholesterol (LDL-
382 C), and triglycerides in CKD. These studies indicated that dyslipidemia can increase the risk of
383 atherosclerotic cardiovascular diseases in patients with CKD [32, 33]. We have previously
384 demonstrated that dyslipidaemia is associated with oxidative stress in diabetes patients with
385 periodontitis, relative to people with diabetes alone [34]. We have also shown the damaging
386 effects of oxidised lipids (from oxLDL) including oxidised cholesterol (27-hydroxycholesterol),
387 using an *in vitro* neuronal cell culture system [35] and on endothelial cells [36].

388 Plasma lipoproteins carry hydrophobic and water insoluble lipids to be delivered to tissue and
389 cells. Phospholipids residing at the surface layer of lipoproteins constituting ∼20–25% of the
390 particle by weight [37] are primary targets of oxidative damage with formation of oxidised
391 phospholipids. Primary oxidation products generated from the most abundant molecular
392 species of PCs (PAPC, SLPC, PLPC and SAPC) are present in LDL [38, 39]. Reis et al., previously
393 compared the molecular lipidomic profile of LDL in patients with non-diabetic, advanced renal
394 disease to that of age-matched controls [40]. The study indicated significantly lower
395 concentrations of PCs in LDL particles. A study conducted by Yang et al., described changes to

the urinary phospholipid profile in CKD patients [41]. Collectively, this work suggested an important link between phospholipid profiles and CKD.

Based on these measures, we sought to investigate whether increased oxidative stress may have contributed to differences in the circulating profile of phosphocholines in patients with CKD with or without periodontitis. Elevated peripheral oxidative stress has been reported in periodontitis, arising from peripheral blood neutrophil activation by periodontal bacteraemia, including extracellular release of reactive oxygen species [42]. While the damage to macromolecules, including phospholipids are inevitable, so far none of the studies have investigated oxidised phospholipid profiles in periodontitis. To our knowledge, this is the first time fragmented oxPCs have been analysed in the plasma of patients with CKD with periodontitis as a comorbid inflammatory disease. This paper has focused on the oxidative modification to PAPC, PLPC, SAPC and SLPC classes of lipids.

HDdiA-PC levels were significantly increased in all patient groups tested and the keto acid analogue, KOOA-PC was significantly higher in the presence of both diseases. These oxPCs share a common structural moiety possessing sn-2 esterified γ-hydroxy (or oxo)-α,β unsaturated carbonyl-containing fatty acids. This suggests that they represent limited oxidation before chain fragmentation to form shorter fatty acid moieties, which may relate to the concentration or nature of radical species involved in oxidation. Eugene et al., described the generation of this family of truncated PCs using unilamellar vesicles in the presence of the myeloperoxidase (MPO)-H_2O_2-NO_2^- system [43]. MPO is most abundantly expressed in neutrophil granules and released either into the phagosome or the extracellular space where it catalyses the conversion of H_2O_2 and chloride in to hypochlorous acid. Therefore, it is possible that neutrophil hyperactivity in chronic periodontitis [42, 44] has a key role in generating this family of PCs.

PCs with an acyl chain at the sn-2 position are known to have high affinity for the macrophage scavenger receptor, CD36 [45]. Chain fragmented oxPCs, such as POVPC, were less effective in binding to the CD36 receptor. Moreover, altering the sn-2 esterified group by repositioning of the γ –hydroxy moiety by one methylene group or completely losing γ –hydroxyl moiety significantly reduced CD36 binding ability. The work by Eugene et al. highlighted the highly conserved nature of the critical structural elements required for oxidised phospholipids to serve as ligands for CD36 and uptake by macrophages [46]. It is established that LDL loaded macrophages can lead to exacerbation of inflammation and involvement in cardiovascular disease pathologies via foam cell formation. The altered oxPC profile observed here may contribute to increased risk for CVD, as observed in patients comorbid for CKD and periodontitis, due to altered clearance by CD36 and binding to pro-inflammatory TLRs [16].

The biological activity of circulating oxPCs is extensive and has been reviewed previously [13, 17]. Using an in vitro approach, Gargalovic et al., have shown that oxPCs at non-toxic concentrations (50 µg/ml) can regulate >1000 genes in endothelial cells [47]. OxPAPC disrupts endothelial barrier properties and activates both pro- and anti-inflammatory pathways [48].

435 OxPAPC altered endothelial transcriptome analysis revealed the complexity of various
436 regulatory pathways [48]. Using a systems level network approach, Hitzel et al., described
437 oxPC regulated amino acid metabolism in endothelial cells [49]. They further demonstrated
438 that oxPAPC induces a gene network regulating serine-glycine metabolism with the
439 mitochondrial methylenetetrahydrofolate dehydrogenase/cyclohydrolase (MTHFD2), which
440 is active in atherosclerotic plaque material with implications in cardiovascular disease.

441 Taken together, this work highlights the importance of accurate measurement of oxPCs within
442 biological fluids and possible implications of disease comorbidities on phosphocholine profile.

443

444 **5. Conclusion**

445 We have developed a quantitative oxPC lipidomic method for application in plasma analysis.
446 This sensitive, accurate and improved method is able to detect differences between healthy
447 people and patients with oxidative stress related diseases. The signature of OxPC found in our
448 study of CKD, with or without periodontal comorbidity, discriminated between the two
449 conditions. This study has potential to help understand any role of oxPCs in the complications
450 of CKD and indicates their potential use as biomarkers for diagnosis, prognosis and treatment.

451

452

453 **6. Acknowledgement**

454 HKID, HRG, ILC and PC gratefully acknowledge support from Kidney Research UK (PDF3/2014).
455 HKID and OSA also acknowledge support from Alzheimer's Research UK network grant 2017.
456 OSA was supported by the Aston Research Centre for Healthy Ageing at Aston University. AR
457 acknowledges the financial support provided by Portuguese National Funds (NORTE-01-0145-
458 FEDER-000011). PC acknowledges the support of the JABBS foundation. PS acknowledge
459 doctoral research fellowship grant by the National Institute of Health Research (NIHR), UK
460 (grant reference: DRF-2014-07-109). The views expressed in this article are those of the
461 authors and not necessarily those of the NHS, the NIHR or the Department of Health.

462

463 **Declarations of interest:** none

464

465

466

467

468 ## 7. References

469 1. Matsushita, K., et al., *Association of estimated glomerular filtration rate and albuminuria*
470 *with all-cause and cardiovascular mortality in general population cohorts: a collaborative*
471 *meta-analysis.* Lancet, 2010. **375**.
472 2. Gansevoort, R.T., et al., *Lower estimated GFR and higher albuminuria are associated with*
473 *adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population*
474 *cohorts.* Kidney Int, 2011. **80**.
475 3. Brenner, B.M., et al., *Effects of losartan on renal and cardiovascular outcomes in patients*
476 *with type 2 diabetes and nephropathy.* N Eng J Med, 2001. **345**.
477 4. Cobo, G., B. Lindholm, and P. Stenvinkel, *Chronic inflammation in end-stage renal disease*
478 *and dialysis.* Nephrology, dialysis, transplantation : official publication of the European
479 Dialysis and Transplant Association - European Renal Association, 2018. **33**(suppl_3): p. iii35-
480 iii40.
481 5. Kassebaum, N.J., et al., *Global burden of severe periodontitis in 1990-2010: a systematic*
482 *review and meta-regression.* Journal of dental research, 2014. **93**(11): p. 1045-1053.
483 6. Tonetti, M.S., et al., *Impact of the global burden of periodontal diseases on health, nutrition*
484 *and wellbeing of mankind: A call for global action.* Journal of Clinical Periodontology, 2017.
485 **44**(5): p. 456-462.
486 7. D'Aiuto, F., D. Ready, and M.S. Tonetti, *Periodontal disease and C-reactive protein-associated*
487 *cardiovascular risk.* Journal of Periodontal Research, 2004. **39**(4): p. 236-241.
488 8. Chapple, I.L.C. and J.B. Matthews, *The role of reactive oxygen and antioxidant species in*
489 *periodontal tissue destruction.* Periodontology 2000, 2007. **43**(1): p. 160-232.
490 9. Stringer, S., et al., *The natural history of, and risk factors for, progressive Chronic Kidney*
491 *Disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol.*
492 BMC Nephrology, 2013. **14**(1): p. 95.
493 10. Sharma, P., et al., *The periodontal health component of the Renal Impairment In Secondary*
494 *Care (RIISC) cohort study: a description of the rationale, methodology and initial baseline*
495 *results.* Journal of Clinical Periodontology, 2014. **41**(7): p. 653-661.
496 11. Sharma, P., et al., *Association between periodontitis and mortality in stages 3–5 chronic*
497 *kidney disease: NHANES III and linked mortality study.* Journal of Clinical Periodontology,
498 2016. **43**(2): p. 104-113.
499 12. Cottone, S., et al., *Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in*
500 *hypertensive patients.* Nephrology Dialysis Transplantation, 2009. **24**(2): p. 497-503.
501 13. Mauerhofer, C., et al., *Hormetic and anti-inflammatory properties of oxidized phospholipids.*
502 Molecular Aspects of Medicine, 2016. **49**: p. 78-90.
503 14. Gruber, F., et al., *A simplified procedure for semi-targeted lipidomic analysis of oxidized*
504 *phosphatidylcholines induced by UVA irradiation.* Journal of Lipid Research, 2012. **53**(6): p.
505 1232-1242.
506 15. Reis, A., et al., *Separation of peroxidation products of diacyl-phosphatidylcholines by*
507 *reversed-phase liquid chromatography–mass spectrometry.* Biomedical Chromatography,
508 2005. **19**(2): p. 129-137.
509 16. O'Donnell VB, R.J., Wakelam MJ, *Phospholipid signaling in innate immune cells.* J Clin Invest.,
510 2018: p. pii: 97944.
511 17. Bochkov, V.N., et al., *Generation and biological activities of oxidized phospholipids.*
512 Antioxidants & redox signaling, 2010. **12**(8): p. 1009-1059.
513 18. Philippova, M., et al., *Analysis of fragmented oxidized phosphatidylcholines in human plasma*
514 *using mass spectrometry: Comparison with immune assays.* Free Radical Biology and
515 Medicine, 2019.
516 19. Reis, A., *Oxidative Phospholipidomics in health and disease: Achievements, challenges and*
517 *hopes.* Free Radical Biology and Medicine, 2017. **111**: p. 25-37.

518 20. Reis, A., et al., *Tandem mass spectrometry of intact oxidation products of*
519 *diacylphosphatidylcholines: evidence for the occurrence of the oxidation of the*
520 *phosphocholine head and differentiation of isomers.* Journal of Mass Spectrometry, 2004.
521 **39**(12): p. 1513-1522.
522 21. Ademowo, O.S., et al., *Phospholipid oxidation and carotenoid supplementation in*
523 *Alzheimer's disease patients.* Free Radical Biology and Medicine, 2017. **108**: p. 77-85.
524 22. Sharma, P., et al., *INfluence of Successful Periodontal Intervention in REnal Disease*
525 *(INSPIRED): study protocol for a randomised controlled pilot clinical trial.* Trials, 2017. **18**(1):
526 p. 535.
527 23. Folch, J., M. Lees, and G.H.S. Stanley, *A SIMPLE METHOD FOR THE ISOLATION AND*
528 *PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES.* Journal of Biological Chemistry,
529 1957. **226**(1): p. 497-509.
530 24. Rouser, G., S. Fleischer, and A. Yamamoto, *Two dimensional thin layer chromatographic*
531 *separation of polar lipids and determination of phospholipids by phosphorus analysis of*
532 *spots.* Lipids, 1970. **5**(5): p. 494-496.
533 25. Dias, I.H.K., et al., *Sulfate-based lipids: Analysis of healthy human fluids and cell extracts.*
534 Chemistry and Physics of Lipids, 2019. **221**: p. 53-64.
535 26. Shrivastava, A. and V. Gupta, *Methods for the determination of limit of detection and limit of*
536 *quantitation of the analytical methods.* Chronicles of Young Scientists, 2011. **2**(1): p. 21-25.
537 27. Matuszewski, B.K., M.L. Constanzer, and C.M. Chavez-Eng, *Strategies for the Assessment of*
538 *Matrix Effect in Quantitative Bioanalytical Methods Based on HPLC–MS/MS.* Analytical
539 Chemistry, 2003. **75**(13): p. 3019-3030.
540 28. Partani, P., S.M. Verma, and T. Monif, *Development and Validation of an LC–MS-MS Method*
541 *for Determination of Simvastatin and Simvastatin Acid in Human Plasma: Application to a*
542 *Pharmacokinetic Study.* Journal of Chromatographic Science, 2016. **54**(8): p. 1385-1396.
543 29. Grubbs, V., et al., *The association of periodontal disease with kidney function decline: a*
544 *longitudinal retrospective analysis of the MrOS dental study.* Nephrology, dialysis,
545 transplantation : official publication of the European Dialysis and Transplant Association -
546 European Renal Association, 2016. **31**(3): p. 466-472.
547 30. Ioannidou, E., et al., *Periodontitis case definition affects the association with renal function in*
548 *kidney transplant recipients.* Oral diseases, 2010. **16**(7): p. 636-642.
549 31. Keane, W.F., J.E. Tomassini, and D.R. Neff, *Lipid Abnormalities in Patients with Chronic*
550 *Kidney Disease: Implications for the Pathophysiology of Atherosclerosis.* Journal of
551 Atherosclerosis and Thrombosis, 2013. **20**(2): p. 123-133.
552 32. Shoji, T., et al., *Elevated Non-high-density Lipoprotein Cholesterol (Non-HDL-C) Predicts*
553 *Atherosclerotic Cardiovascular Events in Hemodialysis Patients.* Clinical Journal of the
554 American Society of Nephrology, 2011. **6**(5): p. 1112-1120.
555 33. Muntner, P., et al., *Traditional and Nontraditional Risk Factors Predict Coronary Heart*
556 *Disease in Chronic Kidney Disease: Results from the Atherosclerosis Risk in Communities*
557 *Study.* Journal of the American Society of Nephrology, 2005. **16**(2): p. 529-538.
558 34. Allen, E.M., et al., *Oxidative and inflammatory status in Type 2 diabetes patients with*
559 *periodontitis.* J Clin Periodontol, 2011. **38**.
560 35. Dias, I.H.K., et al., *Oxidized LDL lipids increase β-amyloid production by SH-SY5Y cells through*
561 *glutathione depletion and lipid raft formation.* Free Radical Biology and Medicine, 2014. **75**:
562 p. 48-59.
563 36. Dias, H.K.I., et al., *LDL-lipids from patients with hypercholesterolaemia and Alzheimer's*
564 *disease are inflammatory to microvascular endothelial cells: mitigation by statin*
565 *intervention.* Clinical Science, 2015. **129**(12): p. 1195-1206.
566 37. Esterbauer, H., et al., *Biochemical structural and functional properties of oxidized low-density*
567 *lipoprotein.* Chemical Research in Toxicology, 1990. **3**(2): p. 77-92.

568 38. Milne, G.L., et al., *Identification and analysis of products formed from phospholipids in the*
569 *free radical oxidation of human low density lipoproteins.* Journal of Lipid Research, 2005.
570 **46**(2): p. 307-319.
571 39. Stübiger, G., et al., *Targeted profiling of atherogenic phospholipids in human plasma and*
572 *lipoproteins of hyperlipidemic patients using MALDI-QIT-TOF-MS/MS.* Atherosclerosis, 2012.
573 **224**(1): p. 177-186.
574 40. Reis, A., et al., *Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in*
575 *advanced chronic kidney disease.* Journal of lipid research, 2015. **56**(2): p. 413-422.
576 41. Yang, W.-L., et al., *Changes of urinary phospholipids in the chronic kidney disease patients.*
577 Biomarkers, 2013. **18**(7): p. 601-606.
578 42. Matthews, J.B., et al., *Hyperactivity and reactivity of peripheral blood neutrophils in chronic*
579 *periodontitis.* Clinical & Experimental Immunology, 2007. **147**(2): p. 255-264.
580 43. Podrez, E.A., et al., *Identification of a Novel Family of Oxidized Phospholipids That Serve as*
581 *Ligands for the Macrophage Scavenger Receptor CD36.* Journal of Biological Chemistry, 2002.
582 **277**(41): p. 38503-38516.
583 44. Dias, I.H.K., et al., *Activation of the neutrophil respiratory burst by plasma from periodontitis*
584 *patients is mediated by pro-inflammatory cytokines.* Journal of Clinical Periodontology, 2011.
585 **38**(1): p. 1-7.
586 45. Hazen, S.L., *Oxidized phospholipids as endogenous pattern recognition ligands in innate*
587 *immunity.* The Journal of biological chemistry, 2008. **283**(23): p. 15527-15531.
588 46. Podrez, E.A., et al., *A Novel Family of Atherogenic Oxidized Phospholipids Promotes*
589 *Macrophage Foam Cell Formation via the Scavenger Receptor CD36 and Is Enriched in*
590 *Atherosclerotic Lesions.* Journal of Biological Chemistry, 2002. **277**(41): p. 38517-38523.
591 47. Gargalovic, P.S., et al., *Identification of inflammatory gene modules based on variations of*
592 *human endothelial cell responses to oxidized lipids.* Proceedings of the National Academy of
593 Sciences, 2006. **103**(34): p. 12741-12746.
594 48. Romanoski, C.E., et al., *Network for activation of human endothelial cells by oxidized*
595 *phospholipids: a critical role of heme oxygenase 1.* Circulation research, 2011. **109**(5): p. e27-
596 e41.
597 49. Hitzel, J., et al., *Oxidized phospholipids regulate amino acid metabolism through MTHFD2 to*
598 *facilitate nucleotide release in endothelial cells.* Nature Communications, 2018. **9**(1): p. 2292.

599

600

601

602

603

604

605

606 **Figures**

607



608

609 **Figure 1: Chromatographic separation of native PAPC, SAPC, PLPC and SLPC standards.**
610 Native PAPC, SAPC, PLPC and SLPC in a positive ion mode revealed single chromatographic
611 peaks that corresponded to the protonated molecule at *m/z* 782.7, *m/z* 810.6, *m/z* 758.7 and
612 *m/z* 786.6 respectively; with their respective spectra in the inserts. Ions observed in LC-MS
613 spectra at *m/z* 804.7, *m/z* 832.6, *m/z*780.7 and *m/z* 808.6 corresponded to sodiated adducts
614 ($[MNa]^+$) of each analyte.

615

616



617

618 **Figure 2: Extracted ion chromatograms (XIC) of individual molecular species of four commercial**
619 **synthetic standards and eight chain fragmented oxPCs.** MRM method developed for 12 oxPCs,
620 which consist of four commercially available standards (POVPC, PONPC, PGPC, PAzPC) and
621 eight iron oxidised products of SAPC and SLPC lipids; namely SOVPC (1-stearoyl-2-(5'-oxo-
622 valeroyl)-*sn*-glycero-3-phosphocholine), SGPC (1-stearoyl-2-glutaryl-*sn*-glycero-3-
623 phosphocholine), SONPC (1-stearoyl -2-(9'-oxo-nonanoyl)-*sn*-glycero-3-phosphocholine)
624 SAzPC (1-stearoyl-2-azelaoyl-sn-glycero-3-phosphocholine), HOOA-PC (1-palmitoyl-2-(5-
625 hydroxy-8-oxo-6-octenoyl)-sn-glycero-3-phosphocholine), KOOA-PC (1-palmitoyl-2-(5-
626 hydroxy-8-oxo-6-octenoic acid)-sn-glycero-3-phosphocholine), KDdiA-PPC (1-palmitoyl-2-(4-
627 keto-dodec-3-enadioyl)-sn-glycero-3-phosphocholine, and HDdiA-PC (1-palmitoyl-2-(9-
628 hydroxy-11-carboxy-undec-6-enoyl)-sn-glycero-3-phosphocholine)
629

630

631



632

633 **Figure 3: Total phospholipid content in disease groups.**

634



635

636 **Figure 4. OxPC concentrations (µmol/L plasma ± SEM) measured in plasma from healthy**
637 **control, patients with periodontitis, patients with CKD and patients with CKD comorbid with**
638 **periodontitis.**

639 **Tables**

640 **Table 1:** Demographics of patients and healthy control individuals

	Healthy control (n=20)	CKD (n=13)	Periodontitis (n=17)	CKD and periodontitis (n=20)	P<0.05
Weight (Kg)	73.95 ± 3.75	83 ± 5.56	78.59 ± 3.63	86.59 ± 5.05	No
BMI (Kg/m^2)	25.5 ± 0.92	28.4 ± 1.39	27.36 ± 0.95	29.96 ± 1.83	No
Age (years)	37 ± 2	74 ± 3	48 ± 1	62 ± 2	Yes
Gender (% female)	60	8	59	30	Yes
Periodontal Health	0	0	1	1	

641

642 **Table 2:** Selected multiple MRM parameters (Q1/Q3 transition pair, declustering potential
643 (DP), collision energy (CE), exit quadrupole potential (CXP), retention times (min) used in the
644 analysis

Analyte	MRM transitions	Dwell Time (ms)	DP (V)	CE (V)	CXP (V)	Retention time (min)
POVPC	594.5/184.0	100	96	33	18	7.76
PGPC	610.0/184.0	100	10	37	26	7.71
PONPC	650.0/184.0	100	10	39	14	8.24
PAzPC	666.0/184.0	100	10	37	16	8.02
SOVPC	622.0/184.0	100	26	45	18	8.23
SGPC	638.0/184.0	100	16	35	10	8.18
SONPC	678.0/184.0	100	16	43	18	8.97
SAzPC	694.0/184.0	100	21	37	24	8.58
HOOA-PC	649.0/184.0	100	31	41	10	8.30

KOOA-PC	648.0/184.0	100	26	41	24	8.35
KDdiA-PC	720.0/184.0	100	6.0	45	16	8.67
HDdiA-PC	722.0/184.0	100	21	37	28	8.65
DMPC (d13)	691.0/481.0	100	96	38	12	9.53

645

646 **Table 3: Multivariable regression analysis of oxPCs between disease groups.** Groups were
647 analysed with measures of oxidative stress as dependent variables and clinical health
648 parameters (healthy/ periodontitis only/ CKD only/ CKD and periodontitis), age and sex as
649 independent variables. Significance was accepted as p<0.05.

	POVPC	SOVPC	HOOA-PC	PONPC	SONPC	KOOA-PC	PGPC	SGPC	HDdiA-PC	PAzPC	SAzpc	KDdiA-PC
Perio vs Healthy	0.023	0.1	0.131	0.087	0.552	0.104	0.2	0.483	0.028	0.71	0.401	0.361
CKD vs Healthy	0.337	0.17	0.99	0.294	0.152	0.258	0.453	0.009	0.000	0.111	0.004	0.404
CKD+Perio vs Healthy	0.797	0.476	0.431	0.454	0.033	0.000	0.491	0.029	0.000	0.028	0.906	0.141
CKD vs Perio	0.004	0.003	0.241	0.929	0.207	0.956	0.054	0.000	0.003	0.027	0.005	0.775
CKD+Perio vs Perio	0.013	0.015	0.019	0.015	0.048	0.000	0.041	0.002	0.001	0.003	0.505	0.386
CKD+Perio vs CKD	0.224	0.219	0.307	0.011	0.592	0.000	0.78	0.161	0.941	0.757	0.000	0.573

650
651